AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00298155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with dutasteride
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
Study NCT04474587 — intervention group
Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Measurements of REE by indirect calorimetry
Study NCT00298155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with bicalutamide and dutasteride
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
Study NCT00298155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with bicalutamide and dutasteride and ketoconazole
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
Study NCT02763098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.1
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study NCT01907646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bladder training
Description: vescical catheter
Study NCT01907646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No bladder training
Study NCT03119662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: 100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
Study NCT03119662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100 mL saline, followed by a 10 mL saline flush.
Study NCT04493879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioptron Light Therapy (BLT)
Description: BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
Study NCT01156441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical mitral valve repair w/ mitral valve annuloplasty
Description: Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers.
Study NCT02763098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.2
Description: .Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study NCT02763098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.3
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study NCT00767715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: physician determined dose, oral, daily, 5 months
Study NCT00586937 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires or telephone interview
Description: In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
Study NCT01885338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Study NCT01885338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo capsule
Study NCT03767387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trimodal Prehabilitation
Description: Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
Study NCT03644758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: socio-demographic data and personal medical history
Description: Socio-demographic data and personal medical history is a self-administered questionnaire.
Study NCT03644758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
Study NCT03644758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Epworth Sleepiness Scale
Description: Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
Study NCT03644758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia Severity Index (ISI)
Description: Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
Study NCT03644758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stop-BANG questionnaire
Description: Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
Study NCT02853773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ingestion of a test meal with sweetener
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
Study NCT02853773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ingestion of a test meal with sweetener
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
Study NCT02853773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ingestion of a test meal with water
Description: participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
Study NCT03191032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early sensory re-education of the hand with a sensor glove model
Description: Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
Study NCT02438397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: premix insulin
Description: Premix-insulin(human insulin or analog) treatment will continue
Study NCT02438397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: premix insulin
Description: Premix-insulin(human insulin or analog) treatment will continue
Study NCT02438397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500 mg tid by Merck
Study NCT02438397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 100mg tid by Bayer
Study NCT03858231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: 1 tablet up to 4 times per day for 7 days
Study NCT03858231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: 1 tablet up to 4 times per day for 7 days
Study NCT03858231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 325Mg Tab
Description: 1 tablet up to 4 times per day for 7 days
Study NCT01210573 — intervention group
Intervention type: DEVICE
Intervention: adjustment of LVAD or pacemaker
Description: For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.
Study NCT00573365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentlewaves Select™ handheld high energy LED array
Description: LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
Study NCT00573365 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Weekly radiation treatment
Study NCT00573365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Weekly radiation treatment
Study NCT04526327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: the combination of aerobic and resistive exercise, three time a week
Study NCT01158703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75mg daily by mouth daily for 12 months
Study NCT01158703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill by mouth daily for 12 months
Study NCT01158703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
Study NCT01158703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
Study NCT00542971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 12 mg/m\^2 IV over 1 hour daily (days 1-3)
Study NCT00542971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 400 mg by mouth for 7 days
Study NCT00542971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 1.5 g/m\^2 IV over 24 hours daily (days 1-4)
Study NCT00767715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
Study NCT00767715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zuclopentixol
Description: physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
Study NCT02800759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JOINTRUS®
Description: 100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
Study NCT02800759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 80% dose of JOINTRUS®
Description: 80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
Study NCT02800759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 62.4% dose of JOINTRUS®
Description: 62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
Study NCT02800759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch 100%
Description: 0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
Study NCT00901927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
Study NCT00901927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
Study NCT00901927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
Study NCT02780609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
Study NCT02780609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 100 mg/m\^2 IV over 30-45 minutes.
Study NCT02780609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
Study NCT02780609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation (HCT)
Description: Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
Study NCT02780609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant at 150 mg IV on days -3 and -2.
Study NCT01008631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Description: 6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
Study NCT02942420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Study NCT03190174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Rapamycin
Description: Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m2; at Dose Level 2, 3-6 six patients will receive 75 mg/m2; and at Dose Level 3, 3-6 patients will receive 100 mg/m2.
Study NCT03190174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
Study NCT02333851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixtard 30:70 Novonordisk® twice daily
Description: Premixed insulin twice daily before breakfast and before dinner
Study NCT02333851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus® once daily and Apidra® before meals
Description: Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
Study NCT01732575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enrichment with meaning-generating activities
Description: Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
Study NCT03700255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PickUpSimTM simulation training program
Description: The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians.
Study NCT01536262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium + Olodaterol
Description: Tiotropium and Olodaterol FDC once daily inhalation
Study NCT01536262 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat
Description: Respimat inhaler
Study NCT01536262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olodaterol
Description: Olodaterol once daily inhalation
Study NCT03609580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin - 1 week
Description: The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
Study NCT03464058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo capsules
Description: Oral capsules
Study NCT03609580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin - 3 days
Description: The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
Study NCT02466737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no axillary surgery versus SLNB
Description: in cases with newly diagnosed breast cancer and clinically negative axillary status
Study NCT00465361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: performance feedback with an educational module
Description: individual performance feedback with an educational module
Study NCT04520243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity assessment by ETDRS charts
Description: All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
Study NCT04520243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity assessment by ETDRS charts
Description: All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
Study NCT03789487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device programming of CRT pacemaker or defibrillator
Description: Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
Study NCT03595241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation by implanted device.
Description: Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
Study NCT01118767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell phone intervention
Description: Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
Study NCT02466737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no axillary surgery versus SLNB
Description: in cases with newly diagnosed breast cancer and clinically negative axillary status
Study NCT02466737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLNB versus completion ALND
Description: in cases with 1-3 macrometastases in sentinel lymph nodes